'On consolidated basis
Quarter ended September 2024 compared with Quarter ended September 2023.
Net sales (including other operating income) of Glaxosmithkline Pharmaceuticals has increased 5.62% to Rs 1010.77 crore. Operating profit margin has jumped from 30.25% to 31.83%, leading to 11.13% rise in operating profit to Rs 321.71 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 9.56% to 15.02%. Purchase of finished goods cost fell from 27.31% to 21.85%. Employee cost decreased from 15.22% to 15.19%. Other expenses fell from 17.59% to 15.51%.
Other income rose 22.44% to Rs 34.54 crore. PBIDT rose 12.13% to Rs 356.25 crore. Provision for interest fell 37.21% to Rs 0.27 crore. Loan funds declined from Rs 21.38 crore as of 30 September 2023 to Rs 14.79 crore as of 30 September 2024. Inventories declined fr...
Pleaselogin & subscribe to view the full report.
More Reports
-
-
Revenue up by 3.3% YoY to Rs 4304.7 crore in Q3FY2025
-
-
|
|